Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France and Arnon Nagler, MD, from the Sheba Medical Center, Tel Hashomer, Israel, discuss the highlights from the second day of the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. First, Prof Nagler highlights the presentations that focused on the current situation in Asia and how therapies for multiple myeloma (MM) all around the world are improving. Prof Mohty also discusses the trials that are being run in China. Prof Nagler and Prof Mohty then discuss the Patient Advocate Meeting and the importance of the patient voice in MM. Prof Mohty further argues that now, new frontiers are being explored in MM and in particular, mentions immunotherapies. According to Prof Nagler, adoptive cellular therapy and monoclonal antibodies will be the future and will replace allogeneic stem cell transplantation. Prof Nagler and Prof Mohty discuss when these new therapies will be in clinical use. Finally, they also talk about the impact of new technologies such as next-generation sequencing (NGS), and how to classify and diagnose MM in future. They conclude, that while a lot has been achieved in MM, a lot remains to be done.